Viatris Inc

Viatris is a pharmaceutical manufacturer operating across developed and emerging markets worldwide. The company develops, manufactures, and distributes prescription brand drugs, generic medications, complex generic formulations, and biosimilars across multiple therapeutic areas including cardiovascular, central nervous system, dermatology, diabetes, oncology, and respiratory conditions. Its portfolio includes established branded medications such as Lyrica, Lipitor, Celebrex, Viagra, and EpiPen Auto-Injector, alongside generic and complex dosage formulations delivered through oral solids, injectables, and specialized delivery systems.

The company operates through four geographic segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets, enabling distribution across North America, Europe, Asia-Pacific, Africa, Latin America, and the Middle East. Products reach customers through pharmaceutical wholesalers and distributors, retail pharmacies, institutional facilities, mail-order services, and specialty pharmacy channels. The company also provides ancillary healthcare services including diagnostic clinics and digital health management tools to support patient outcomes.

With approximately 30,000 full-time employees and headquarters in Canonsburg, Pennsylvania, Viatris maintains significant scale in the global pharmaceutical market. The company has established collaboration agreements with external partners for biosimilar development and commercialization, including arrangements with Revance Therapeutics and Theravance Biopharma to expand its specialized product offerings.